有癌症史的炎症性肠病患者免疫抑制治疗安全性的前瞻性队列研究:SAPPHIRE注册研究
SAPPHIRE前瞻性注册研究纳入305例有癌症史的炎症性肠病患者,中位随访4.8年,69%暴露于免疫抑制治疗,15%发生新发癌症。未调整分析中暴露组粗发生率为4.78/100人年,未暴露组为2.58/100人年(相对风险1.85,95%CI 0.92-3.73);调整后未发现免疫抑制与 incident cancer 的显著关联(调整风险比1.41,95%CI 0.69-2.90)。
要点
- 有癌症史的炎症性肠病患者中,免疫抑制暴露与 incident cancer 无显著统计学关联(调整HR 1.41,95%CI 0.69-2.90)。
- 未调整分析中暴露组粗发生率为4.78/100人年,未暴露组为2.58/100人年(RR 1.85,95%CI 0.92-3.73)。
- 中位随访4.8年期间,46例(15%)发生 incident cancer,其中25例新发、21例复发。
核心结论
- 在有癌症史的炎症性肠病患者中,尽管调整后风险比数值升高,但未发现后续免疫抑制治疗暴露与 incident cancer 发生之间存在统计学显著关联。
研究设计与样本
- SAPPHIRE为前瞻性注册研究,自2016年起每年随访入组前已确诊索引癌症的炎症性肠病患者。
- 共纳入305例患者(47%男性,88%白人),诊断炎症性肠病和癌症的中位年龄分别为32岁和52岁。
- 排除入组时正在接受化疗或放疗者,或5年内癌症复发者。
主要发现
- 索引癌症类型为实体器官(46%)、皮肤(32%)、胃肠道(13%)和血液系统(9%)。
- 中位随访4.8年期间,210例(69%)暴露于免疫抑制治疗,46例(15%)发生 incident cancer(25例新发,21例复发)。
- 未调整分析中,未暴露组 incident cancer 粗发生率为2.58/100人年,暴露组为4.78/100人年(相对风险1.85,95%CI 0.92-3.73)。
- 在调整性别、吸烟史、索引恶性肿瘤时年龄和分期以及非黑色素瘤皮肤癌的时变比例风险模型中,接受免疫抑制与 incident cancer 无显著关联(调整风险比1.41,95%CI 0.69-2.90),与任何主要药物类别也无显著关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In patients with inflammatory bowel disease (IBD) and a history of cancer, retrospective studies have suggested that exposure to immunosuppressive agents does not increase the risk of incident (recurrent or new) cancer compared with unexposed patients. Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients and a HIstoRy of CancEr (SAPPHIRE) is a prospective registry aimed at addressing this issue. METHODS: Since 2016, patients with IBD and confirmed index cancer before enrollment were followed up annually. Patients receiving chemotherapy or radiation at enrollment, or recurrent cancer within 5 years, were excluded. The primary outcome was development of incident cancer related to exposure to immunosuppressive medications. RESULTS: Among 305 patients (47% male, 88% white), the median age at IBD diagnosis and cancer were 32 and 52 years, respectively. Index cancers were solid organ (46%), dermatologic (32%), gastrointestinal (13%), and hematologic (9%). During a median follow-up period of 4.8 years, 210 patients (69%) were exposed to immunosuppressive therapy and 46 patients (15%) developed incident cancers (25 new, 21 recurrent). In unadjusted analysis, the crude rate of incident cancer in unexposed patients was 2.58 per 100 person-years vs 4.78 per 100 person-years (relative risk, 1.85; 95% CI, 0.92-3.73) for immunosuppression-exposed patients. In a time-varying proportional hazards model adjusting for sex, smoking history, age and stage at index malignancy, and nonmelanoma skin cancer, no significant association was found between receipt of immunosuppression and incident cancer (adjusted hazard ratio, 1.41; 95% CI, 0.69-2.90), or with any major drug class. CONCLUSIONS: In this interim analysis of patients with IBD and a history of cancer, despite numerically increased adjusted hazard ratios, we did not find a statistically significant association between subsequent exposure to immunosuppressive therapies and development of incident cancers.
引用
- Itzkowitz SH, Jiang Y, Villagra C, et al. Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE Registry. Clin Gastroenterol Hepatol. 2024. PMID: 38768673. doi:10.1016/j.cgh.2024.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。